30.08.19
Copenhagen, Denmark, August 28, 2019 – Orphazyme A/S (ticker: ORPHA.CO), a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, today announces its interim financial results for the period January 1 – June 30, 2019 and corporate highlights...
Read more11.08.19
Mallinckrodt answer questions from the NPC community regarding the suspension of VTS-270 301 in UK and France...
Read more02.08.19
The following article features a letter regarding the Study 301 Suspension from Sheila Talafous, Director of Advocacy Relations at Mallinckrodt Pharmaceuticals...
Read more26.07.19
We are pleased to inform you of a study opportunity available to NPC patients and their families:
Clinical Outcomes Solutions (COS), is a research company conducting research into Niemann-Pick type C (NPC) on behalf of a sponsor, Orphazyme A/S, a pharmaceutical company studying NPC...
22.07.19
Following the encouraging regulatory agency feedback, Orphazyme plans to introduce an Early Access
Program for NPC in the fall of 2019, to further accelerate access to treatment with arimoclomol for people
living with NPC...
